NCT07525960招募中1 期
A Phase 1b, Open-label Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of NDI-5001 in a Capsule Following Daily Oral Doses to Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus
Otsuka Pharmaceutical Development & Commercialization, Inc.4 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年7月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 4
- 主要终点
- Percentage Change From Baseline in 24-Hour Urine Volume (Uvol)
研究概览
简要总结
The primary purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NDI-5001 administered as a capsule following daily oral dosing in adult males with X-linked congenital nephrogenic diabetes insipidus (NDI) due to vasopressin receptor Type 2 (V2R) mutations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •X-linked congenital NDI with a genotype-confirmed arginine vasopressin receptor 2 (gene) (AVPR2) mutation and no mutation in aquaporin-2 (AQP2).
- •Urine osmolality of ≤ 200 milliosmoles per kilogram of water (mOsm/kg) in a spot urine sample obtained from a first morning void upon awakening (at screening, check-in [Day -4], and Day -1) before consuming any food or drink after awakening.
- •3) BMI between 18.0 to 32.0 kilograms per square meter (kg/m^2), inclusive.
排除标准
- •Participant who is not willing to follow a low-sodium (<=1 gram/day) diet during the in-clinic portion of the trial.
- •A positive drug screen for substances of abuse (including THC, cannabidiol) at screening or check-in.
- •Estimated glomerular filtration rate <60 milliliters per minute per 1.73-kilogram square meters by serum creatinine and cystatin C at screening.
- •Participants who have taken an investigational drug within 30 days prior to screening.
- •Previous exposure to NDI-
- •Any history of significant bleeding or hemorrhagic tendencies.
- •Note: Other protocol-specified inclusion/exclusion criteria may apply.
研究组 & 干预措施
NDI-5001
Experimental
Participants receive NDI-5001, orally, once daily (QD), for 9 consecutive days starting on Day 1.
干预措施: NDI-5001 (Drug)
结局指标
主要结局
Percentage Change From Baseline in 24-Hour Urine Volume (Uvol)
时间窗: Up to Day 10
Percentage Change From Baseline in Spot Urine Osmolality (Uosm)
时间窗: Up to Day 10
次要结局
- Change From Time-Matched Baseline in Uosm(Up to Day 10)
- Change From Baseline in 24-Hour Uosm(Up to Day 10)
- Number of Participants With Adverse Events (AEs)(Up to Day 39)
- Correlation Coefficient Between 24-Hour Uvol and Uvol by interval(Up to Day 10)
- Correlation Coefficient Between 24-Hour Uvol and Uosm by Interval(Up to Day 10)
- Correlation Coefficient Between 24-Hour Uvol and Spot Uosm(Up to Day 10)
- Number of Participants With Clinically Relevant Changes in Clinical Laboratory Values(Up to Day 31)
- Correlation Coefficient Between Change From Baseline in Uvol and Change From Baseline in Uosm by Interval(Up to Day 10)
- Change From Time-Matched Baseline in Uvol(Up to Day 10)
- Number of Participants With Potentially Clinically Relevant Changes in Vital Signs(Up to Day 31)
- Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings(Up to Day 10)
- Number of Participants With Potentially Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Parameters(Up to Day 10)
- Maximum (Peak) Plasma Concentration (Cmax) of NDI-5001(Day 1 and Day 9)
- Time to Reach Maximum (Peak) Observed Plasma Concentration (Tmax) of NDI-5001(Day 1 and Day 9)
- Area Under the Concentration-time Curve From Time Zero to 24 hours (AUC0-24h) of NDI-5001(Up to 24 hours, post dose on Day 1 and Day 9)
- Dose-Normalized Maximum Observed Plasma Concentration (Cmax/Dose) of NDI-5001(Day 1 and Day 9)
- Dose-Normalized Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24h/Dose) of NDI-5001(Up to 24 hours, post dose on Day 1 and Day 9)
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese SubjectsDeliriumNCT07422142Kunming Pharmaceuticals, Inc.54
招募中
1 期
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular CarcinomaNCT07478302Suzhou Suncadia Biopharmaceuticals Co., Ltd.36
招募中
1 期
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsNCT07263594DualityBio Inc.127
尚未招募
1 期
QLS5132 Combination Therapy in Advanced Solid TumorsOvarian CancerNCT07453394Qilu Pharmaceutical Co., Ltd.626
进行中（未招募）
1 期
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid TumorsNCT07407985Tianjin Medical University Cancer Institute and Hospital15